Xconomy’s Digital Events →
John Mendlein of Fathe Therapeutics (left), Paul Schimmel of The Scripps Research Institute (right)
Sponsored · Whitepaper
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
From Our Editors · Podcast
Becoming the Cell & Gene Therapy Hub
Sponsored · Webinar
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
© 2007-2022, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.